The efficacy and safety of subcutaneous tocilizumab ( TCZ-SC ) versus subcutaneous placebo ( PBO-SC ) was evaluated in patients with rheumatoid arthritis who had an inadequate response to disease-modifying antirheumatic drugs in the BREVACTA study .